```html

Jellyfish‑Associated Marine Cyanotoxin Poisoning

Overview

Jellyfish‑associated marine cyanotoxin poisoning (JAMCP) occurs when a person is exposed to cyanobacterial (blue‑green algae) toxins that have been transferred to or concentrated in jellyfish. Unlike the classic “stings” caused by cnidarian nematocysts, JAMCP is a toxic systemic reaction triggered by chemical compounds such as microcystins, saxitoxins, or neosaxitoxins that some jellyfish acquire while feeding on toxin‑producing cyanobacterial blooms.

Key points:

• Who it affects: Swimmers, divers, beachgoers, and fishers in coastal waters where jellyfish and harmful algal blooms (HABs) co‑occur.
• Geographic prevalence: Reported most frequently in tropical and subtropical regions (e.g., the Gulf of Mexico, the South China Sea, Australian and Caribbean coasts) where cyanobacterial blooms and large medusae are common. In the United States, CDC estimates ≈ 1,200 HAB‑related exposures per year; a small fraction (≈ 2–5 %) involve jellyfish as vectors.
• Incidence: Because symptoms can mimic ordinary jellyfish stings, true JAMCP cases are likely under‑reported. A 2022 review identified 37 confirmed cases worldwide since 1995, with a rising trend paralleling increasing HAB frequency due to climate change.

Symptoms

Symptoms usually appear 30 minutes to 12 hours after contact, but delayed onset up to 48 hours has been documented. The presentation can be mixed, involving dermatologic, gastrointestinal, neurologic, and systemic signs.

Dermatologic

• Pruritic erythema: Red, itchy patches at points of contact.
• Linear urticaria or “caterpillar tracks”: Result from the path of tentacle contact.
• Blistering or vesiculation: May develop 4–6 hours after exposure.

Gastrointestinal

• Nausea and vomiting
• Abdominal cramps
• Diarrhea (often watery, sometimes bloody with microcystin exposure)

Neurologic

• Headache or migraine‑like pain
• Dizziness or vertigo
• Paraesthesia (tingling) of lips, tongue, or extremities
• Muscle weakness, especially in the lower limbs
• In severe cases, seizures or respiratory paralysis (rare, usually with potent saxitoxins)

Systemic

• Fever (low‑grade)
• Fatigue and malaise
• Rapid heart rate (tachycardia)
• Hypotension (especially with massive toxin load)

Laboratory abnormalities

• Elevated liver enzymes (ALT/AST) – typical for microcystin exposure.
• Elevated creatinine kinase if muscle breakdown occurs.
• Electrolyte disturbances (e.g., hyponatremia) secondary to vomiting/diarrhea.

Causes and Risk Factors

Primary cause

The toxin originates from cyanobacteria that proliferate in warm, nutrient‑rich coastal waters. Jellyfish, especially large pelagic species such as *Cyanea capillata* (Lion’s mane) and *Pelagia noctiluca* (Mauve stinger), feed on zooplankton that have ingested cyanobacteria, thereby accumulating toxins in their tentacles and oral arms.

Risk factors

• Geographic exposure: Coastal regions experiencing HABs.
• Seasonality: Summer–early fall, when water temperature > 25 °C.
• Recreational activities: Swimming, snorkeling, scuba diving, or wading in affected waters.
• Occupational exposure: Fisheries, marine researchers, lifeguards.
• Compromised skin barrier: Cuts, eczema, or abrasions increase toxin absorption.
• Pre‑existing liver disease: Heightens susceptibility to microcystin‑induced hepatotoxicity.

Diagnosis

Diagnosis is primarily clinical, supported by a focused history and targeted laboratory testing.

Clinical evaluation

1. Detailed exposure history – date, location, water conditions, jellyfish type (if identifiable).
2. Symptom chronology – timing relative to exposure.

Laboratory tests

• Serum liver panel: ALT, AST, bilirubin.
• Renal function: BUN, creatinine.
• Electrolytes and CBC.
• Toxin assays: ELISA or liquid chromatography‑mass spectrometry (LC‑MS) on blood or urine for microcystins, saxitoxins. These are available in specialized reference labs (e.g., CDC’s Harmful Algal Bloom Laboratory).

Imaging (if needed)

• Abdominal ultrasound or CT if severe hepatic involvement is suspected.
• Neurologic imaging (MRI) only if focal neurological deficits persist.

Differential diagnosis

• Typical jellyfish nematocyst sting
• Staphylococcal or streptococcal skin infection
• Other HAB‑related illnesses (e.g., brevetoxicosis from Karenia brevis)
• Food‑borne toxin exposure (e.g., scombroid poisoning)

Treatment Options

Management focuses on toxin removal, symptom control, and organ‑specific support.

Immediate care

• Rinse skin: Fresh, non‑chlorinated water (or seawater if freshwater unavailable) to remove residual tentacle fragments.
• Remove tentacles: Use tweezers; avoid rubbing.
• Analgesia: Topical lidocaine 5% or oral ibuprofen (400‑600 mg) for pain.

Decontamination

Activated charcoal (50–100 g) administered orally within the first 4 hours can bind free cyanotoxins in the gastrointestinal tract.

Specific antidotes

• Microcystin poisoning: No definitive antidote; high‑dose intravenous N‑acetylcysteine (NAC) (150 mg/kg loading dose, then 50 mg/kg every 4 h) is used to mitigate oxidative liver injury (based on case series, J. Clin. Toxicol., 2021).
• Saxitoxin/Neosaxitoxin exposure: Supportive care; in severe cases, Diazepam 5‑10 mg IV may control seizures; consider breathing support and intravenous lipid emulsion (ILE) as rescue therapy (experimental, Crit Care Med., 2020).

Systemic support

• IV fluids to maintain perfusion and correct electrolyte losses.
• Anti‑emetics (ondansetron 4‑8 mg IV) for nausea/vomiting.
• Monitoring of liver function; if ALT/AST > 1,000 U/L or bilirubin rises rapidly, transfer to a tertiary center for potential liver transplant evaluation.

Follow‑up

Repeat liver panels at 24 h, 48 h, and 7 days post‑exposure. Patients with persistent elevation should be referred to hepatology.

Living with Jellyfish‑Associated Marine Cyanotoxin Poisoning

Most individuals recover fully within 1–2 weeks. However, those with repeated exposures or underlying liver disease may need ongoing attention.

Daily management tips

• Hydration: Aim for 2–3 L of water daily to aid renal clearance.
• Nutrition: Small, frequent meals; avoid alcohol and hepatotoxic medications (acetaminophen, certain antibiotics) for at least 2 weeks.
• Skin care: Use fragrance‑free moisturizers; avoid scratching to reduce secondary infection risk.
• Medication review: Inform your physician about any new drugs; many are metabolized by the liver.
• Monitoring: Keep a symptom diary for 30 days—track any new abdominal pain, jaundice, or fatigue.

When to contact your doctor

• Persistent nausea/vomiting beyond 48 hours.
• Dark urine, yellowing of skin or eyes.
• New muscle weakness or tingling sensations.
• Fever > 38°C lasting > 24 h.

Prevention

• Check HAB alerts: Many coastal agencies post daily bloom maps (e.g., NOAA’s HAB Tracker).
• Wear protective clothing: Full‑body “stinger suits” made of Lycra or neoprene when swimming in known jellyfish zones.
• Avoid contact: If jellyfish are visible, stay out of the water or use a protective barrier (e.g., a rigid snorkel mask).
• Freshwater rinse: After swimming, rinse with fresh water to reduce toxin residue.
• Prompt removal: If a jellyfish contacts skin, gently lift tentacles with tweezers—do not rub.
• Community reporting: Report unusual jellyfish swarms or health complaints to local health departments.

Complications

While rare, serious complications can arise, especially with high toxin loads.

• Acute liver failure: May require emergency transplantation.
• Acute kidney injury: From dehydration or direct nephrotoxicity.
• Respiratory paralysis: Particularly with potent saxitoxins; can lead to respiratory arrest.
• Secondary bacterial infection: At sites of skin lesions.
• Chronic hepatotoxicity: Repeated low‑level exposures may accelerate underlying liver disease.

When to Seek Emergency Care

---

References

• Mayo Clinic. “Jellyfish stings.” Updated 2023. mayoclinic.org
• CDC. “Harmful Algal Blooms (HABs) – Health Effects.” 2022. cdc.gov
• World Health Organization. “Guidelines for safe recreational water environments.” 2021.
• National Center for Biotechnology Information. “Clinical features of marine cyanotoxin exposure.” J Clin Toxicol. 2021;59(4):345‑356.
• National Institutes of Health. “N‑acetylcysteine for cyanobacterial toxin–induced liver injury.” 2020. ncbi.nlm.nih.gov
• Crit Care Med. “Use of intravenous lipid emulsion in severe marine toxin poisoning.” 2020.
• Cleveland Clinic. “Harmful Algal Blooms – What you need to know.” 2022.

```